



19 December 2022

## ASX Announcement

### Notice of Change of Auditor

MELBOURNE Australia, 19 December 2022: Australian mid-clinical stage antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA; "Island"; "the Company") announces that William Buck Audit (Vic) Pty Ltd (William Buck) has been appointed as the Company's auditor with effect from Monday, 19 December 2022.

The appointment follows a tender process, the resignation of Grant Thornton Audit Pty Ltd and receipt of ASIC's consent to the same.

In accordance with 327C(2) of the Corporations Act 2001 (Cth), William Buck will hold office until the Company's next Annual General Meeting at which time shareholders will be requested to formally approve the appointment of the new auditor.

The Board would like to take this opportunity to thank Grant Thornton and their team for their services and support to the Company.

#### Approved for release to the ASX by:

Dr Paul MacLeman  
Executive Chairman  
Island Pharmaceuticals Ltd  
[info@islandpharmaceuticals.com](mailto:info@islandpharmaceuticals.com)

Investors and media, for further information, please contact: `

Jane Lowe  
IR Department  
Mobile: +61 411 117 774  
[jane.lowe@irdepartment.com.au](mailto:jane.lowe@irdepartment.com.au)

#### About Island Pharmaceuticals

---

Island (ASX: ILA) is a mid-clinical-stage drug repurposing company, focused on the topical area of antiviral therapeutics for infectious diseases. Our lead asset is ISLA-101, a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue<sup>2</sup> fever and other mosquito (or vector) borne diseases. The Company is close to commencing a Phase 2a clinical trial in dengue-infected subjects.

If ISLA-101 achieves FDA approval, and certain other criteria are met, Island may be eligible to obtain a "Priority Review Voucher" at the time of FDA approval. This means that as well as getting approval to manufacture and sell ISLA-101, the Priority Review Voucher (PRV) could permit Island to expedite the FDA approval process for a new drug or sell the PRV in a secondary market.

*Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website.*

Visit [www.islandpharmaceuticals.com](http://www.islandpharmaceuticals.com) for more on Island.